FR2321275A1 - INSULIN PREPARATION FOR NASAL ADMINISTRATION - Google Patents

INSULIN PREPARATION FOR NASAL ADMINISTRATION

Info

Publication number
FR2321275A1
FR2321275A1 FR7614707A FR7614707A FR2321275A1 FR 2321275 A1 FR2321275 A1 FR 2321275A1 FR 7614707 A FR7614707 A FR 7614707A FR 7614707 A FR7614707 A FR 7614707A FR 2321275 A1 FR2321275 A1 FR 2321275A1
Authority
FR
France
Prior art keywords
nasal administration
insulin preparation
insulin
preparation
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7614707A
Other languages
French (fr)
Other versions
FR2321275B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FR2321275A1 publication Critical patent/FR2321275A1/en
Application granted granted Critical
Publication of FR2321275B1 publication Critical patent/FR2321275B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
FR7614707A 1975-08-20 1976-05-14 INSULIN PREPARATION FOR NASAL ADMINISTRATION Granted FR2321275A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB34576/75A GB1527605A (en) 1975-08-20 1975-08-20 Insulin preparation for intranasal administration

Publications (2)

Publication Number Publication Date
FR2321275A1 true FR2321275A1 (en) 1977-03-18
FR2321275B1 FR2321275B1 (en) 1979-04-13

Family

ID=10367351

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7614707A Granted FR2321275A1 (en) 1975-08-20 1976-05-14 INSULIN PREPARATION FOR NASAL ADMINISTRATION

Country Status (5)

Country Link
JP (1) JPS6030651B2 (en)
BE (1) BE841871A (en)
DE (1) DE2620446A1 (en)
FR (1) FR2321275A1 (en)
GB (1) GB1527605A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533826A1 (en) * 1982-10-05 1984-04-06 Sandoz Sa Compsn. for nasal admin. contg. calcitonin
EP0111841A1 (en) * 1982-12-10 1984-06-27 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
EP0200383A2 (en) * 1985-04-15 1986-11-05 Eli Lilly And Company An improved method for administering insulin
EP0214898A2 (en) * 1985-08-16 1987-03-18 Merck & Co. Inc. Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
EP0215697A2 (en) * 1985-08-16 1987-03-25 Merck & Co. Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
EP0285367A2 (en) * 1987-04-01 1988-10-05 Temple University of the Commonwealth System of Higher Education Pharmaceutical composition

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5145405A (en) * 1974-10-16 1976-04-17 Unyusho Kowan Gijutsu Kenkyush JIBAN KAIRYOKOHO
JPS53115509A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Method of changing weak ground into stable ground
JPS53115510A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Support structure made by hardening weak soil
DE2917535C2 (en) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Insulin solutions resistant to denaturation
WO1983000288A1 (en) * 1981-07-17 1983-02-03 Balschmidt, Per A stable aqueous, therapeutic insulin preparation and a process for preparing it
IL70489A0 (en) * 1982-12-29 1984-03-30 Armour Pharma Pharmaceutical compositions containing calcitonin
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
DE3443877A1 (en) * 1984-06-09 1985-12-12 Hoechst Ag Insulin preparations, process for their preparation, and their use
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
AU584184B2 (en) * 1985-04-15 1989-05-18 Eli Lilly And Company An improved method for administering insulin
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
DK179286D0 (en) * 1986-04-18 1986-04-18 Nordisk Gentofte INSULIN PREPARATION
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
JPH0713372B2 (en) * 1989-02-14 1995-02-15 鹿島建設株式会社 Construction method of structure foundation in sandy soil layer
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes
JPH04126437U (en) * 1991-05-10 1992-11-18 八木アンテナ株式会社 optical receiver
US5338837A (en) * 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5639866A (en) * 1993-02-23 1997-06-17 Princeton University Single-step formation of multiple glycosidic linkages
JPH08511234A (en) * 1993-02-23 1996-11-26 ザ トラスティーズ オブ プリンストン ユニヴァーシティー Solution and solid phase formation of glycosidic bonds
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ES2218543T3 (en) 1994-03-07 2004-11-16 Nektar Therapeutics PROCEDURE AND PREPARATION FOR THE ADMINISTRATION OF INSULIN BY PULMONARY ROUTE.
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
JP3687993B2 (en) * 1994-06-24 2005-08-24 シスメックス株式会社 Insulin standard solution
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
MX9704550A (en) 1994-12-22 1997-10-31 Astra Ab Aerosol drug formulations.
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
WO2010043566A2 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
PL2498802T3 (en) 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
AU2010360116B2 (en) 2010-08-30 2014-06-26 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP5906194B2 (en) * 2011-01-13 2016-04-20 株式会社カネカ Skin preparation
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
HUE062573T2 (en) 2014-12-12 2023-11-28 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62232C (en) * 1900-01-01
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62232C (en) * 1900-01-01
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533826A1 (en) * 1982-10-05 1984-04-06 Sandoz Sa Compsn. for nasal admin. contg. calcitonin
EP0111841A1 (en) * 1982-12-10 1984-06-27 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
EP0200383A2 (en) * 1985-04-15 1986-11-05 Eli Lilly And Company An improved method for administering insulin
EP0200383A3 (en) * 1985-04-15 1987-09-02 Eli Lilly And Company An improved method for administering insulin
EP0214898A2 (en) * 1985-08-16 1987-03-18 Merck & Co. Inc. Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
EP0215697A2 (en) * 1985-08-16 1987-03-25 Merck & Co. Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
EP0214898A3 (en) * 1985-08-16 1987-06-24 Merck & Co. Inc. Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
EP0215697A3 (en) * 1985-08-16 1987-06-24 Merck & Co. Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
EP0285367A2 (en) * 1987-04-01 1988-10-05 Temple University of the Commonwealth System of Higher Education Pharmaceutical composition
EP0285367A3 (en) * 1987-04-01 1990-03-14 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method for intranasal administration

Also Published As

Publication number Publication date
BE841871A (en) 1976-11-16
JPS6030651B2 (en) 1985-07-17
JPS5225013A (en) 1977-02-24
DE2620446A1 (en) 1977-03-03
FR2321275B1 (en) 1979-04-13
GB1527605A (en) 1978-10-04

Similar Documents

Publication Publication Date Title
FR2321275A1 (en) INSULIN PREPARATION FOR NASAL ADMINISTRATION
FR2313914A1 (en) STABLE INSULIN PREPARATION FOR NASAL ADMINISTRATION
BE837472A (en) INHALER FOR THE ADMINISTRATION OF PULVERULENT REMEDIES
PH23643A (en) Nasal pharmaceutical composition
RO73466A (en) DEVICE FOR THE INHALATION OF MEDICAMENTS
BE849632A (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
IT1081933B (en) DEVICE FOR INHALATION OF POWDER MEDICATIONS
IT1081486B (en) DEVICE FOR INHALATION OF POWDER MEDICATIONS
FR2326941A1 (en) HEMODIALYSIS NEEDLE
FR2297056A1 (en) PULVERULENT INHALER
ZA794786B (en) "inhaler for medication"
GB2014953A (en) Intravenous administration set
BE849257A (en) INHALATION DEVICE
BE886531A (en) DEVICE FOR ADMINISTERING MEDICINES BY INHALATION
FR2285895A1 (en) MEDICINAL SUPPORTS
NZ184060A (en) Sprayable pharmaceutical composition for topical administration
FR2300578A1 (en) MEDICINE INJECTION DEVICE
FR2332766A1 (en) INJECTION SYRINGE
BE854150A (en) ANALGESIC PHARMACEUTICAL COMPOSITION
FR2323039A1 (en) PRIMING DEVICE FOR PUMPS
BE845613A (en) PHARMACEUTICAL PREPARATIONS FOR ORAL ADMINISTRATION CONTAINING NANDROLONE ESTER-17BETA AND NEW NANDROLONE ESTERS-17BETA
FR2351972A1 (en) HETEROARYLBENZOXEPINE-ACETIC ACID PRECURSORS
FR2297055A1 (en) DEVICE FOR INHALING PULVERULENT REMEDIES
FR2315284A1 (en) DEVICE FOR ADMINISTERING AN ANESTHESIC TO A PATIENT
BE833394A (en) PHARMACEUTICAL COMPOSITION INTENDED TO FACILITATE DELIVERY

Legal Events

Date Code Title Description
ST Notification of lapse